Literature DB >> 25120063

ARID3B expression in primary breast cancers and breast cancer-derived cell lines.

Ayse Selcen Oguz Erdogan1, Nihan Ozdemirler, Merve Oyken, Murat Alper, Ayse Elif Erson-Bensan.   

Abstract

BACKGROUND: ARID3B (AT-rich interaction domain 3) is a member of the family of ARID proteins, which constitutes evolutionarily conserved transcription factors implicated in normal development, differentiation, cell cycle regulation and chromatin remodeling. In addition, ARID3B has been linked to cellular immortalization, epithelial-mesenchymal transition (EMT) and tumorigenesis. Given the emerging role of ARID3B in tumor development, we examined its expression in primary patient-derived breast cancer samples and breast cancer-derived cell lines.
METHODS: Immunohistochemistry (IHC) was used to detect ARID3B expression in 63 formalin-fixed paraffin-embedded (FFPE) invasive breast cancer samples. In addition, a panel of 6 (estrogen receptor-positive and -negative, ERBB2-positive and -negative) breast cancer-derived cell lines and immortalized non-tumorigenic epithelial breast cells were used for ARID3B expression analysis using RT-PCR. Specific primers and Western blotting were used to detect ARID3B isoforms.
RESULTS: Using IHC, nuclear, cytoplasmic and low levels of membranous ARID3B staining were detected in all 63 primary invasive breast tumors. Nuclear ARID3B staining positively correlated with estrogen receptor (ER) status and negatively correlated with tumor grade, mitotic index and ERBB2 status of the patients. Increased nuclear expression of ARID3B was confirmed in breast cancer-derived cell lines expressing ERα. In addition, two out of three ERBB2-positive breast cancer cell lines were found to lack full length ARID3B. Three ARID3B isoforms were found to be present in normal breast epithelial cells as well as in breast cancer cells.
CONCLUSION: We report a positive correlation between ER positivity and nuclear ARID3B expression in primary breast cancers, along with a negative correlation with the ERBB2 status. Very similar correlations were noted in breast cancer-derived cell lines. Since in the recent past ARID3B expression has increasingly been related to cancer-associated proteins and microRNAs, knowledge on ARID3B expression and function may be instrumental for gaining further insight into potentially important cancer-related networks.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25120063     DOI: 10.1007/s13402-014-0185-5

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  22 in total

Review 1.  ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development.

Authors:  Deborah Wilsker; Antonia Patsialou; Peter B Dallas; Elizabeth Moran
Journal:  Cell Growth Differ       Date:  2002-03

2.  The human genome browser at UCSC.

Authors:  W James Kent; Charles W Sugnet; Terrence S Furey; Krishna M Roskin; Tom H Pringle; Alan M Zahler; David Haussler
Journal:  Genome Res       Date:  2002-06       Impact factor: 9.043

3.  miR-125b targets ARID3B in breast cancer cells.

Authors:  Shiva Akhavantabasi; Aysegul Sapmaz; Serkan Tuna; Ayse Elif Erson-Bensan
Journal:  Cell Struct Funct       Date:  2012       Impact factor: 2.212

4.  Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.

Authors:  Gary K Scott; Andrei Goga; Dipa Bhaumik; Crystal E Berger; Christopher S Sullivan; Christopher C Benz
Journal:  J Biol Chem       Date:  2006-11-16       Impact factor: 5.157

5.  Differential expression of ARID3B in normal adult tissue and carcinomas.

Authors:  Serene J Samyesudhas; Lynn Roy; Karen D Cowden Dahl
Journal:  Gene       Date:  2014-04-03       Impact factor: 3.688

Review 6.  miRNAs in head and neck cancer revisited.

Authors:  Rahul Nagadia; Pratibala Pandit; William B Coman; Justin Cooper-White; Chamindie Punyadeera
Journal:  Cell Oncol (Dordr)       Date:  2013-01-22       Impact factor: 6.730

7.  Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn.

Authors:  K Kobayashi; L M Jakt; S-I Nishikawa
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

Review 8.  Chromosome 15q24 microdeletion syndrome.

Authors:  Pilar L Magoulas; Ayman W El-Hattab
Journal:  Orphanet J Rare Dis       Date:  2012-01-04       Impact factor: 4.123

9.  ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death.

Authors:  Stancy Joseph; Victoria E Deneke; Karen D Cowden Dahl
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

Review 10.  Recent advances in the ARID family: focusing on roles in human cancer.

Authors:  Chen Lin; Wei Song; Xinyu Bi; Jianjun Zhao; Zhen Huang; Zhiyu Li; Jianguo Zhou; Jianqiang Cai; Hong Zhao
Journal:  Onco Targets Ther       Date:  2014-02-18       Impact factor: 4.147

View more
  3 in total

1.  KLF15 in breast cancer: a novel tumor suppressor?

Authors:  Tomomi Yoda; Keely May McNamara; Yasuhiro Miki; Yoshiaki Onodera; Kiyoshi Takagi; Yasuhiro Nakamura; Takanori Ishida; Takashi Suzuki; Noriaki Ohuchi; Hironobu Sasano
Journal:  Cell Oncol (Dordr)       Date:  2015-04-14       Impact factor: 6.730

2.  Expression and prognostic values of ARID family members in breast cancer.

Authors:  Jinfeng Zhang; Siyu Hou; Zilong You; Guozheng Li; Shouping Xu; Xianyong Li; Xianyu Zhang; Bo Lei; Da Pang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

3.  ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.

Authors:  Jennifer J Wood; James R Boyne; Christina Paulus; Brian R Jackson; Michael M Nevels; Adrian Whitehouse; David J Hughes
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.